Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jennifer E Sager"'
Autor:
Jennifer E. Sager, Asma El‐Zailik, Julie Passarell, Stefan Roepcke, Xiaobin Li, Melissa Aldinger, Ahmed Nader, Andrew Skingsley, Elizabeth L. Alexander, Wendy W. Yeh, Erik Mogalian, Chad Garner, Amanda Peppercorn, Adrienne E. Shapiro, Maribel Reyes
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 6, Pp 853-864 (2023)
Abstract Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death in non‐hospitalized high‐risk patients with mild to moderate coronavirus disease 2019 following either intraveno
Externí odkaz:
https://doaj.org/article/cbe6ae0867b34de2a58be3d836855df3
Autor:
Adrienne E. Shapiro, Elias Sarkis, Jude Acloque, Almena Free, Yaneicy Gonzalez-Rojas, Rubaba Hussain, Erick Juarez, Jaynier Moya, Naval Parikh, David Inman, Deborah Cebrik, Ahmed Nader, Nadia Noormohamed, Qianwen Wang, Andrew Skingsley, Daren Austin, Amanda Peppercorn, Maria L. Agostini, Sergio Parra, Sophia Chow, Erik Mogalian, Phillip S. Pang, David K. Hong, Jennifer E. Sager, Wendy W. Yeh, Elizabeth L. Alexander, Leah A. Gaffney, Anita Kohli
BackgroundConvenient administration of coronavirus disease 2019 (COVID-19) treatment in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action monoclonal antibody formulated for intravenous (IV) or intramuscular (IM) administra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6eb08d2911a70bce8dc0f30cdc3cae2d
https://doi.org/10.1101/2023.03.21.23287410
https://doi.org/10.1101/2023.03.21.23287410
Autor:
Arisa OKAMASA, Malek OKOUR, Daren AUSTIN, Yuri SHIDA, Jennifer E. SAGER, Elizabeth ALEXANDER, Dimitra BRINTZIKI, Amina HAGGAG, Stephen A. HARRISON, Takako HATTORI, Ian HAWES, Nobuhiko OKUDA, Scott SEGAL, Andrew SKINGSLEY, Robert WILLIAMS, Esther YOON, Andrew M. LIPPA
Publikováno v:
Kansenshogaku Zasshi. 96:39-45
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::183a4ef44b5728e181056776f559cd06
https://doi.org/10.11150/kansenshogakuzasshi.96.39
https://doi.org/10.11150/kansenshogakuzasshi.96.39
Autor:
Jaynier Moya, Marisol Temech, Sergio Parra, Erick Juarez, Reinaldo Hernandez-Loy, Juan C. Moises Gutierrez, Jorge Diaz, Rubaba Hussain, Scott Segal, Claire Xu, Andrew Skingsley, Gretja Schnell, Asma El-Zailik, Jennifer E. Sager, Melissa Aldinger, Elizabeth L. Alexander, Gerard Acloque
Background500 mg intravenous (IV) sotrovimab has been shown to be well tolerated and efficacious against pre-Omicron strains in treating patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk for disease progression.MethodsTh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7a956eed5166eb2c79e0fb1444f47c3
https://doi.org/10.1101/2023.02.02.23285352
https://doi.org/10.1101/2023.02.02.23285352
Autor:
Jennifer E. Sager, Asma El-Zailik, Julie Passarell, Stefan Roepcke, Xiaobin Li, Melissa Aldinger, Ahmed Nader, Andrew Skingsley, Elizabeth L. Alexander, Wendy W. Yeh, Erik Mogalian, Chad Garner, Amanda Peppercorn, Adrienne E. Shapiro, Maribel Reyes
Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death from severe disease in non-hospitalized high-risk patients with mild-to-moderate COVID-19 following either intravenous (IV) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50daa9d72af5e188fcade20242b1de3c
https://doi.org/10.1101/2022.11.23.22282478
https://doi.org/10.1101/2022.11.23.22282478
Autor:
Anil, Gupta, Yaneicy, Gonzalez-Rojas, Erick, Juarez, Manuel, Crespo Casal, Jaynier, Moya, Diego, Rodrigues Falci, Elias, Sarkis, Joel, Solis, Hanzhe, Zheng, Nicola, Scott, Andrea L, Cathcart, Sergio, Parra, Jennifer E, Sager, Daren, Austin, Amanda, Peppercorn, Elizabeth, Alexander, Wendy W, Yeh, Cynthia, Brinson, Melissa, Aldinger, Adrienne E, Shapiro, Lawrence, Sher
Publikováno v:
JAMA
IMPORTANCE: Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of high-risk patients to prevent COVID-19 progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3072af5f0c357da130288d9bee64ef34
https://pubmed.ncbi.nlm.nih.gov/35285853
https://pubmed.ncbi.nlm.nih.gov/35285853
Autor:
Adrienne E. Shapiro, Elias Sarkis, Jude Acloque, Almena Free, Yaneicy Gonazalez-Rojas, Rubaba Hussain, Erick Juarez, Jaynier Moya, Naval Parikh, David Inman, Deborah Cebrik, Ahmed Nadeer, Nadia Noormohamed, Qianwen Wang, Andrew Skingsley, Daren Austin, Amanda Peppercorn, Sergio Parra, Sophia Chow, Erik Mogalian, Phillip S. Pang, David K. Hong, Jennifer E. Sager, Wendy W. Yeh, Elizabeth Alexander, Leah A. Gaffney, Anita Kohli
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3752de56eceb4b7a72aa696a1c003010
https://doi.org/10.2139/ssrn.4111060
https://doi.org/10.2139/ssrn.4111060
Autor:
Alyssa Stephenson-Famy, Lindsay C. Czuba, Emily E. Fay, Sara Shum, Nina Isoherranen, Jennifer E Sager
Publikováno v:
Ther Drug Monit
Background Bupropion (BUP) is a chiral antidepressant and smoking cessation aide with benefits and side effects correlated with parent and active metabolite concentrations. BUP is metabolized by CYP2B6, CYP2C19, and CYP3A4 to hydroxy-BUP (OH-BUP), an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cf6258f094689ecf6723b8333cb7286
https://europepmc.org/articles/PMC8426418/
https://europepmc.org/articles/PMC8426418/
Publikováno v:
Drug Metabolism and Disposition. 45:1156-1165
Physiologically based pharmacokinetic (PBPK) modeling of drug disposition and drug-drug interactions (DDIs) has become a key component of drug development. PBPK modeling has also been considered as an approach to predict drug disposition in special p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea76de029399818f3306e5e0dc82ac42
https://doi.org/10.1124/dmd.117.076455
https://doi.org/10.1124/dmd.117.076455
Autor:
Hong Tsao, Yongkai Sun, Paresh P. Chothe, Amanda Moore, Leena Laitinen, Jennifer E. Sager, Niresh Hariparsad
Publikováno v:
Drug Metabolism and Disposition. 45:692-705
Typically, concentration-response curves are based upon nominal inducer concentrations for in-vitro-to-in-vivo extrapolation of CYP3A4 induction. The limitation of this practice is that it assumes the hepatocyte culture model is a static system. We a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0459581a368a4e777d9e59a6aa0d2ef0
https://doi.org/10.1124/dmd.117.075481
https://doi.org/10.1124/dmd.117.075481